Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/43338
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorGonzález Cardenete, Miguel Ángel-
dc.contributor.authorHamulić, Damir-
dc.contributor.authorMiquel Leal, Francisco-
dc.contributor.authorGonzález Zapata, Natalia-
dc.contributor.authorJiménez Jarava, Orlando José-
dc.contributor.authorMiranda Brand, Yaneth-
dc.contributor.authorRestrepo Mendez, Laura-
dc.contributor.authorMartínez Gutiérrez, Marlen-
dc.contributor.authorBetancur Galvis, Liliana Amparo-
dc.contributor.authorMarín, María-
dc.date.accessioned2024-11-10T16:45:05Z-
dc.date.available2024-11-10T16:45:05Z-
dc.date.issued2022-
dc.identifier.citationGonzález-Cardenete MA, Hamulić D, Miquel-Leal FJ, González-Zapata N, Jimenez-Jarava OJ, Brand YM, Restrepo-Mendez LC, Martinez-Gutierrez M, Betancur-Galvis LA, Marín ML. Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids. J Nat Prod. 2022 Aug 26;85(8):2044-2051. doi: 10.1021/acs.jnatprod.2c00464.spa
dc.identifier.issn0163-3864-
dc.identifier.urihttps://hdl.handle.net/10495/43338-
dc.description.abstractABSTRACT: Viral infections affect several million patients annually. Although hundreds of viruses are known to be pathogenic, only a few can be treated in the clinic with available antiviral drugs. Naturally based pharmacotherapy may be a proper alternative for treating viral diseases. Several natural and semisynthetic abietane-type diterpenoids have shown important antiviral activities. In this study, a biological evaluation of a number of either C-18- or C-19-functionalized known semisynthetic abietanes against Zika virus, Dengue virus, Herpes virus simplex type 1, and Chikungunya virus are reported. Semisynthetic abietane ferruginol and its analogue 18-(phthalimid-2-yl)ferruginol displayed broad-spectrum antiviral properties. The scale-up synthesis of this analogue has been optimized for further studies and development. This molecule displayed an EC50 between 5.0 and 10.0 μM against Colombian Zika virus strains and EC50 = 9.8 μM against Chikungunya virus. Knowing that this ferruginol analogue is also active against Dengue virus type 2 (EC50 = 1.4 μM, DENV-2), we can conclude that this compound is a promising broad-spectrum antiviral agent paving the way for the development of novel antivirals.spa
dc.format.extent8 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherAmerican Chemical Societyspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleAntiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoidsspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGRID - Grupo de Investigación Dermatológicaspa
dc.publisher.groupGrupo de Investigación en Microbiología Básica y Aplicada-Microbaspa
dc.identifier.doi10.1021/acs.jnatprod.2c00464-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1520-6025-
oaire.citationtitleJournal of Natural Productsspa
oaire.citationstartpage2044spa
oaire.citationendpage2051spa
oaire.citationvolume85spa
oaire.citationissue8spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
oaire.fundernameUniversidad de Antioquia. Vicerrectoría de investigación. Comité para el Desarrollo de la Investigación - CODIspa
oaire.fundernameColombia. Ministerio de Ciencia, Tecnología e Innovación - MinCienciasspa
dc.publisher.placeCincinnati, Estados Unidosspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAbietanos-
dc.subject.decsAbietanes-
dc.subject.decsAntivirales-
dc.subject.decsAntiviral Agents-
dc.subject.decsVirus Chikungunya-
dc.subject.decsChikungunya virus-
dc.subject.decsReplicación Viral-
dc.subject.decsVirus Replication-
dc.subject.decsVirus-
dc.subject.decsViruses-
dc.subject.decsInfección por el Virus Zika-
dc.subject.decsZika Virus Infection-
dc.description.researchgroupidCOL0126131spa
dc.description.researchgroupidCOL0050839spa
oaire.awardnumberMinCiencias 111574455595spa
oaire.awardnumberMinCiencias 141577757439spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D045784-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000998-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D002646-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D014779-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D014780-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000071243-
dc.relation.ispartofjournalabbrevJ. Nat. Prod.spa
oaire.funderidentifier.rorRoR:03bp5hc83-
oaire.funderidentifier.rorRoR:03fd5ne08-
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
JimenezOrlando_2022_Antiviral_Profiling_C-18-C-19-.pdfArtículo de investigación3.68 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons